ATXI - アベニュ―・セラピュ―ティクス （Avenue Therapeutics Inc.）

Avenue Therapeutics (ATXI) was trading around +4% on Tuesday after reporting progress in its efforts to secure approval for a Phase 3 clinical trial of its intravenous Tramadol.The…

MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has received official meeting minutes from the Type C meeting with the U.S. Food and Drug Administration (“FDA”) conducted on March 9, 2023, regarding the development of intravenous (“IV”) Tramadol for the treatment of post-operative pain. The purpose of this meeting was to discuss and reach agreement with the FDA on the proposed study protocol that would assess the risk of opioid-induced respiratory depression related to opioid stacking on IV Tramadol compared to IV morphine.

https://www.investing.com/news/assorted/avenue-therapeutics-announces-194m-share-offering-by-selling-stockholders-432SI-3052308

Avenue Therapeutics press release (ATXI): FY GAAP EPS of -$1.63.As of December 31, 2022, our cash and cash equivalents totaled $6.7 million, compared to $3.8 million at December 31,…

Ocean Biomedical OCEA +57%. Avenue Therapeutics (ATXI) +21%. InVivo Therapeutics NVIV -49%. Akebia Therapeutics (AKBA) -22%.

NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Therapeutics, Inc. Avenue Therapeutics, Inc. (Nasdaq:ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. Avenue is headquartered in Miami, Florida and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, please visit: https://www.avenuetx.com About Aegis Capital Corporation Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

Continue reading on Medium »

The share price of Avenue Therapeutics Inc. (NASDAQ:ATXI) rose to $1.50 per share on Friday from $1.49. While Avenue Therapeutics Inc. has overperformed by 0.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATXI fell by -87.65%, with highs and lows ranging from $18.75 to $1.06, […]

Avenue Therapeutics Inc. (NASDAQ:ATXI) shares, rose in value on Wednesday, 01/18/23, with the stock price down by -21.11% to the previous day’s close as strong demand from buyers drove the stock to $1.57. Actively observing the price movement in the last trading, the stock closed the session at $1.99, falling within a range of $1.57 … Is Avenue Therapeutics Inc. (NASDAQ: ATXI) A Stock A New Investor Should Consider Now? Read More »

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Pre-Market Steady Movements: Avenue Therapeutics, Inc. (NASDAQ:ATXI -21.11%), Invitae Corporation (NYSE:NVTA -2.27%) appeared first on Stocks Equity .

During the last session, Avenue Therapeutics Inc. (NASDAQ:ATXI)’s traded shares were 1.31 million, with the beta value of the company hitting -0.56. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday gain of 7.83% or $0.13. The 52-week high for the ATXI share is $26.85, that puts it down … Is Avenue Therapeutics Inc. (NASDAQ: ATXI) Still A Buy After sinking -4.79% Last Week? Read More »

Avenue Therapeutics press release (ATXI): Q3 GAAP EPS of -$0.45.As of September 30, 2022, Avenue’s cash and cash equivalents totaled $0.2M, compared to $3.8M at December 31, 2021.

The share price of Avenue Therapeutics Inc. (NASDAQ:ATXI) fell to $1.78 per share on Friday from $1.99. While Avenue Therapeutics Inc. has underperformed by -10.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATXI fell by -92.67%, with highs and lows ranging from $27.75 to $1.98, […]

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.37% to 29,927.92 while the NASDAQ fell 1.44% to 10,495.56. The S&P 500 also fell, dropping, 0.98% to 3,634.00. Also check this: Market Volatility Declines Following US Inflation Data Leading and Lagging Sectors Health care shares fell by just 0.4% on Friday. Leading the sector was strength from Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) and Valneva SE (NASDAQ: VALN ). In trading on Friday, energy shares dipped by 2.9%. Top Headline US retail trade came in unchanged for September, missing market estimates for a 0.2% rise. Equities Trading UP Gravitas Education Holdings, Inc. (NASDAQ: GEHI ) shares shot up 78% to $26.65. Shares of Avenue Therapeutics, Inc. (NASDAQ: ATXI ) got a boost, shooting 43% to $3.4806. Avenue Therapeutics recently priced a roughly 3.6 million unit offering at $3.30 per unit. IMARA Inc. (NASDAQ: IMRA ) shares were also up, gaining 35% to $3.47 after the …

Avenue Therapeutics (ATXI) is down 10.8% after-hours after the firm has priced its underwritten public offering of 3,636,365 common and pre-funded units.Each common unit consists of…